Skip to main content
x
Norris Cotton Cancer Center
In This Section

Blood Cancer Program Clinical Trials

Clinical trials are research studies that evaluate the effect of a medical, surgical, or behavioral treatment. They are the main way that researchers find out if a new drug, diet or medical device (for example, a pacemaker) is safe and effective for use in people. Often a clinical trial is used to learn if a new treatment is more effective or has less harmful side effects than the standard treatment currently used. It is the last stage of a long and careful research process. 

The following is a list of clinical trials with which this cancer care program is currently involved. Talk to your doctor to find out if a clinical trial is right for you, or you are eligible.

Hodgkins Lymphoma Clinical Trials
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
Hodgkins Lymphoma
D16127
Meehan
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Hodgkins Lymphoma
C50801
Bengtson
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Hodgkins Lymphoma
B0943
Hill
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Hodgkins Lymphoma
B0944
Hill
Umbrella Long-Term Follow Up Protocol
Hodgkins Lymphoma
ALTE05N1
Kim
Leukemia, Other Clinical Trials
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
Leukemia, Other
D16127
Meehan
Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Leukemia, Other
F16066
Lansigan
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Leukemia, Other
B0943
Hill
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Leukemia, Other
B0944
Hill
Leukemia, not otherwise specified Clinical Trials
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Leukemia, not otherwise specified
B0943
Hill
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Leukemia, not otherwise specified
B0944
Hill
The CALGB Leukemia Tissue Bank
Leukemia, not otherwise specified
C9665
Lowrey
Umbrella Long-Term Follow Up Protocol
Leukemia, not otherwise specified
ALTE05N1
Kim
Lymphoid Leukemia Clinical Trials
A Phase I Trial of BNC105P and Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Lymphoid Leukemia
D17093
Lewis
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Lymphoid Leukemia
E1910
Yerrabothala
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
Lymphoid Leukemia
D16127
Meehan
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Lymphoid Leukemia
B0943
Hill
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Lymphoid Leukemia
B0944
Hill
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Lymphoid Leukemia
AALL1331
Kim
Multiple Myeloma Clinical Trials
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
Multiple Myeloma
D16127
Meehan
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Multiple Myeloma
B0943
Hill
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Multiple Myeloma
B0944
Hill
Mycosis Fungoides Clinical Trials
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Mycosis Fungoides
B0943
Hill
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Mycosis Fungoides
B0944
Hill
Myeloid and Monocytic Leukemia Clinical Trials
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
Myeloid and Monocytic Leukemia
D16127
Meehan
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Myeloid and Monocytic Leukemia
B0943
Hill
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Myeloid and Monocytic Leukemia
B0944
Hill
Randomized Phase II Study To Assess The Role Of Nivolumab As Single Agent To Eliminate Minimal Residual Disease And Maintain Remission In Acute Myelogenous Leukemia (AML) Patients After Chemotherapy
Myeloid and Monocytic Leukemia
ETCTN9706
Lowrey
Non-Hodgkins Lymphoma Clinical Trials
A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-Programmed Death-1 Monoclonal Antibody, in Patients with B-Cell Malignancies
Non-Hodgkins Lymphoma
F16043
Lansigan
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkins Lymphoma
Non-Hodgkins Lymphoma
F16129
Lansigan
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
Non-Hodgkins Lymphoma
D16127
Meehan
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1?
Non-Hodgkins Lymphoma
F18142
Lansigan
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Non-Hodgkins Lymphoma
EA4151
Lansigan
Molecular Analysis for Therapy Choice (MATCH)
Non-Hodgkins Lymphoma
EAY131
Dragnev
Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
Non-Hodgkins Lymphoma
ETCTN9875
Lansigan
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Non-Hodgkins Lymphoma
B0943
Hill
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Non-Hodgkins Lymphoma
B0944
Hill
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
Non-Hodgkins Lymphoma
E1412
Lansigan
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Non-Hodgkins Lymphoma
S1608
Lansigan
Other Hematopoietic Clinical Trials
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Other Hematopoietic
F18013
Drescher
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
Other Hematopoietic
D16127
Meehan
A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
Other Hematopoietic
EAQ152
Dragnev
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
Other Hematopoietic
H17031
Drescher
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors
Other Hematopoietic
B0942
Meehan
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Other Hematopoietic
B0943
Hill
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Other Hematopoietic
B0944
Hill
Contact Us

0